Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06857240 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to Jun 1, 2025
    v4
  3. Secondary endpoints: details revised at 1 of 1 entryv3
  4. Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
Trial Details
NCT Number NCT06857240
Lead Sponsor The Cleveland Clinic
Conditions
(from sponsor)		 Dermatomyositis
Related terms Dermatomyositis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov